Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-IgE antibody trial in IgE-ACPA positive rheumatoid arthritis
NL-OMON28491Phase 2Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Omalizumab with Placebo (2 arms). Primary endpoints: Clinical disease activity response by DAS44, Peripheral blood and synovial immunological parameters and 1 more. Planned start Jan 2011; status: not yet recruiting.
02
Drugs
omalizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON28491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28491.